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Recurrent respiratory papillomatosis (RRP), a chronic upper respiratory condition characterized by diffuse multiple
recurring papillomas, is thought to result from human papillomavirus (HPV) type 6 or 11 infection. Although RRP is
an intractable disease, malignant transformation of RRP is rare. The underlying mechanism, however, has not been
elucidated. We describe the clinical course of a patient who underwent more than 130 operations for RRP
associated with HPV type 6 infection and subsequently suffered spontaneous malignant transformation to
squamous cell carcinoma. Immunohistochemical analysis revealed that malignant transformation might result from
a genomic defect, such as p53 inactivation, leading to stimulation of uncontrolled cell proliferation by HPV type 6
for an extended period, but not directly because of HPV itself. Our results could help in the development of novel
therapeutic strategies for severe RRP, although further studies are required before clinical application of molecular
targeted therapies.
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Recurrent respiratory papillomatosis (RRP), usually a
benign disease, is a chronic upper respiratory condition
characterized by the occurrence of diffuse multiple
recurring papillomas, which are caused by infection with
human papillomavirus (HPV) type 6 and/or 11 (Go et al.
2003; Katsenos & Becker 2011). RRP has a bimodal age
distribution with peaks of incidence at 5 and 20–30 years
of age, corresponding to juvenile-onset and adult-onset
RRP, respectively (Hall et al. 2011). In juvenile-onset
cases, a number of different drugs have previously been
used as adjuvant therapy, including antiviral agents,
interferon, retinoids (Katsenos & Becker 2011; Gallagher
& Derkay 2009) and cidofovir, but their efficacies are* Correspondence: kanatake@omiya.jichi.ac.jp
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Surgical removal of respiratory tract papilloma is the
primary treatment for RRP, but it is also used as palliative
treatment for the prevention of severe dyspnea and stridor
(Bergler & Gotte 2000; Preuss et al. 2007). Thus, many
patients require multiple surgeries and each episode of
surgery or surgical trauma can result in the reemergence or
worsening of the papillomas (Preuss et al. 2007).
Both HPV types 6 and 11, which cause RRP, are
considered to be low-risk oncogenic HPVs, and malignant
transformation is a rare occurrence. Data from clinical
cases has however indicated that HPV type 11 is associated
with a greater risk of malignant transformation than HPV
type 6 (Reidy et al. 2004; Gerein et al. 2005).
Here, we report a case of RRP that underwent spontan-
eous malignant transformation to squamous cell carcinoma
(SCC) after more than 130 operations, and which was,
unusually, associated with HPV type 6 infection. We also
identified protein markers of proliferation and neoplasticis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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nant transformation in this case.
Case presentation
The patient in this case was a 39-year-old Japanese man
with a history of RRP, who had presented with progressive
hoarseness when he was 1 year old and was diagnosed with
laryngeal papilloma by biopsy under general anesthesia
3 years later. Surgical excision and laser ablation were
performed, but the papillomas immediately recurred and
resulted again in severe dyspnea. When the patient was
6 years old, a tracheotomy was performed to relieve severe
dyspnea. During this procedure, a large papilloma was
discovered. RRP was diagnosed, and the patient was
followed-up at our hospital. Initially, various treatments
were tried including interferon-α, interferon-β, interferon-γ,
acyclovir, fluorouracil, retinoids, and traditional Chinese
medicines, but none of these treatments resulted in a
significant clinical response.
The tumors originated in the larynx, gradually increased
in size, and progressed to the tracheal bifurcation,
although the pathological diagnosis was still one of mild
dysplasia. Thus, treatment was continued in the form of
repeated surgical reductions of the papilloma using an
endoscopic microdebrider or potassium-titanyl-phosphate
(KTP) laser to maintain the airway over the next 35 years.
This involved more than 130 procedures. In 2011,
granulation tissue around the tracheotomy aperture
was found to have increased and a biopsy revealed
indicated SCC. A larynx biopsy performed at the same
time revealed additional moderate dysplasia but not
malignancy. This patient received irradiation by accelerated
hyperfractionation resulting in good local control, but he
died from metastasis to the lung.
RRP is a potentially devastating disease that can be
associated with significant morbidity, and result in
mortality due to airway compromise even if not changeFigure 1 Hematoxylin eosin stain. The specimen obtained from the laryn
tumor tissue around the tracheotomy aperture in 2011 (F).to malignant. However, malignant transformation is not
commonly seen, and thus, the underlying mechanism is
still unclear. In an attempt to determine the mechanism
of malignant transformation in this case, HPV typing
and diachronic immunohistochemistry were performed.
HPV typing by multiplex-PCR detected HPV type 6 infec-
tion but not evidence of “high-risk” type HPV infection.
We performed immunohistochemistry on specimens
obtained from the larynx in 1989, 1994, 2000, 2005, and
2011, and on the tumor tissue obtained from around the
tracheotomy aperture in 2011. All specimens from the
larynx showed mild to moderate dysplasia (Figure 1A, B,
C, D, and E), but the specimen from around the trache-
otomy aperture showed SCC (Figure 1F) on hematoxylin
and eosin (HE) staining. Diachronic HE staining revealed
that there was no progress of dysplasia towards malig-
nancy until a SCC was detected in the tissue around the
tracheotomy aperture in 2011. The level of p16 staining
diachronically increased in parts of the dysplastic tissue
(Figure 2A, B, C, D, and E) but p16 staining was not
positive in the SCC removed from the tumor tissue
around the tracheotomy aperture (Figure 2F). In addition,
the dysplastic tissue was negative for p53 staining
(Figure 3A, B, C, D, and E), but the SCC showed strong
positive staining for this marker (Figure 3F).
Both the dysplastic tissue and the SCC stained
strongly positive for epidermal growth factor receptor
(EGFR, Figure 4A and D). In order to investigate possible
differences in EGFR signaling between the dysplastic tissue
and the SCC, we also used immunohistochemistry to
detect the key proteins of the EGFR signaling pathway:
phosphorylated EGFR (pEGFR), phosphorylated extracel-
lular signal-regulated kinase (pERK), and phosphorylated
AKT (pAKT). Staining was positive for pEGFR (Figure 4B)
and pERK (Figure 4C) and negative for pAKT in the
dysplastic tissue, whereas staining for pEGFR (Figure 4E),
pERK (Figure 4F), and pAKT was negative in the SCC.x in 1989 (A), 1994 (B), 2000 (C), 2005 (D), and 2011 (E), and from the
Figure 2 Immunohistochemical analysis of p16. The specimens obtained from the larynx in 1989 (A), 1994 (B), 2000 (C), 2005 (D),and 2011 (E),
and from the tumor tissue around the tracheotomy aperture in 2011 (F).
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Table 1.
Discussion
RRP is a rare condition characterized by recurrent
growth of benign papillomas in the respiratory tract, and
is now known to be caused exclusively by HPV, usually
type 6 and/or 11 (Go et al. 2003; Katsenos & Becker 2011).
The disease presents in 2 forms according to age at onset.
Juvenile RRP, which occurs in patients under 5 years,
is considered more aggressive than the adult type
(Hall et al. 2011). Juvenile RRP is a severe and potentially
fatal disease because it can result in airway obstruction on
multiple recurrence (Kimberlin & Malis 2000).
Various treatments for RRP using antiviral therapies
including interferon, retinoids, photodynamic therapy,
zinc, anti-reflux medications, cyclooxygenase-2 inhibitors,
therapeutic/preventive vaccines, and gene therapy have
been trialled (Katsenos & Becker 2011; Gallagher & Derkay
2009). One therapy in particular, intralesional injection ofFigure 3 Immunohistochemical analysis of p53. The specimens obtaine
and from the tumor tissue around the tracheotomy aperture in 2011 (F).the anti-viral agent cidofovir, has shown particular promise
(Shehab et al. 2005; Kimberlin & Malis 2000). However, it
is known that cidofovior has a malignant transformation
risk and the link between cidofovir and malignancy is very
currently topic, thus it is not covered by National Health
Insurance in Japan and we could not use it. Although other
various treatments were used in this case, few curative
effects were observed. This case required more than 130
surgical debulking procedures using an endoscopic
microdebrider or KTP laser to maintain the airway over
a period of 35 years.
RRP is considered to be an intractable disease as it
generally does not respond to therapeutic interventions,
but malignant transformation is very rare, occurring in
only 1–4% of patients with RRP (Jeong et al. 2009). A
malignant transformation rate of 1.7% was reported in a
series of 179 patients (Klozar et al. 1997), and malignant
transformation or secondary airway carcinoma were
observed in 4% of 194 patients in another large-scale study
(Preuss et al. 2007).d from the larynx in 1989 (A), 1994 (B), 2000 (C), 2005 (D),and 2011 (E),
Figure 4 Immunohistochemical staining for EGFR signaling. EGFR (A), pEGFR (B), and pERK (C) in the dysplastic sample obtained in 2011, and
for EGFR(D), pEGFR (E), and pERK (F) in the SCC sample.
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transformation of RRP is still unknown, but risk factors
include smoking, prior irradiation, juvenile onset, and the
type of infecting HPV (Katsenos & Becker 2011). HPV
types 6 and 11 are the most frequent detectable genotypes
in RRP specimens, but HPV type 11-positive patients are
characterized by more aggressive RRP, a more frequent
requirement for tracheotomy, malignant transformation,
and mortality during follow-up (Gerein et al. 2005).
To date, two mechanisms for malignant transformation
of RRP associated with HPV type 11 infection have been
reported. Reidy et al. showed that HPV type 11 genes can
integrate into the host genome, and the three oncogenic
proteins, E5, E6, and E7 produced by the integrated HPV
have been implicated as malignant transforming factors
(Reidy et al. 2004). This process is the same as that known
to underlie the malignant conversion of “high-risk” types of
papillomavirus in cervical intraepithelial neoplasia. Products
of the E6 and E7 genes degrade p53 and retinoblastoma
protein, and the E5 gene product stimulates EGFR activa-
tion to induce cell proliferation (Kim et al. 2010). Other
studies also demonstrated that p53 is overexpressed in the
carcinoma component of RRP associated with HPV type 11
infection, suggesting the presence of another mechanismTable 1 Summary of immunohistochemistry
A B C D E F
HE dysplasia dysplasia dysplasia dysplasia dysplasia SCC
p16 mild mild moderate moderate strong negative
p53 mild mild mild mild mild strong
EGFR strong strong strong strong strong strong
pEGFR positive negative
pERK positive negative
Specimens obtained from the larynx in 1989 (A), 1994 (B), 2000 (C), 2005
(D), and 2011 (E), and on the tumor tissue obtained from around the
tracheotomy aperture in 2011 (F).(Go et al. 2003; Rady et al. 1998; Stern et al. 2000). Previous
reports have mainly examined the mechanism of malignant
transformation in RRP resulting from HPV type 11
infection, and only a few concerned RRP associated
with HPV type 6 infection.
The patient in the present case was diagnosed with
juvenile RRP associated with infection by HPV type 6,
with no history of smoking and previous irradiation,
making this a very unusual case of malignant transform-
ation. There are a number of possible explanations for the
occurrence of malignant transformation in this relatively
low-risk case, including re-infection by “high-risk” HPVs,
an enhancement of the oncogenic potential of the existing
HPV type 6 infection, the activation of oncogenic proteins
in the papilloma cells because of increased cellular prolifer-
ation, or an inhibition of tumor suppressor genes.
In this study, we evaluated the expression of p16,
known to be a surrogate marker for “high risk” HPV
infection but not yet ill-defined for “low-risk” HPV
infection. The strength of p16 staining was diachronic-
ally increased in the dysplastic tissue, but p16 staining
was negative in the SCC. This suggests that the multiplicity
of infection or the oncogenic potential of HPV was dia-
chronically increased if p16 staining acts as a surrogate
marker, but the malignant transformation might not have
been a result of HPV infection. Furthermore, EGFR, a
known oncogene in head and neck cancer that is activated
by the product of the HPV E5 gene (Kim et al. 2010), was
strongly expressed in the initial papilloma stage and at all
subsequent stages through to SCC. However, only the
dysplastic tissue was positive for pEGFR and pERK
staining, indicating that the EGFR signaling pathway
might be activated in dysplastic tissue but not SCC.
These results indicate HPV type 6 is not capable of
mediating a malignant transformation but that it can
potentially increase cell proliferation. This increased
cell proliferation in turn facilitated a significant genetic
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staining became positive.
It is noteworthy that the multi functional tumor
suppressor gene, p53, was not expressed in dysplastic tis-
sue but was strongly expressed after malignant transform-
ation to SCC. It is well-established that the E5 gene
product of HPV types 16 or 18 can inactivate p53 function
leading to malignant transformation (Kim et al. 2010) and
that p53 is wild type but not expressed in cervical cancers,
although some cervical cancers do express mutant p53 and
not infected by HPV. Unlike cervical cancers, malignant
transformation in this case might have been contributed to
by a mutation in p53, leading in turn to enhanced cell
proliferative stimulation by HPV type 6 over an extended
period. This is distinct, however, from a direct oncogenic
effect of HPV.
The relationship between p53 expression and malignant
transformation is still unclear. Some previous studies
reported progressively increased expression of p53 and
suggested that this was a significant event in the progres-
sion to SCC (Stern et al. 2000; Lin et al. 2010). Although
our observation supports the concept that p53 is related
to malignant transformation, another study reported that
p53 protein overexpression was present in both papillo-
mas and carcinomas at variable levels in the epithelium
without any consistent pattern (Go et al. 2003). Taken
together, it seems likely that there is no unique mechanism
responsible for the malignant transformation of RRP and
that the chronic proliferative stimulation resulting from
HPV infection leads to genomic instability. Thus, these
cancers may be very difficult to histologically and clinically
diagnose early in the course of transformation.
Malignant transformation of RRP is almost impossible
to treat. Antiviral agents and interferon have shown
some promise, but unfortunately very mild curative
effects. Therefore, novel treatments are needed for RRP
before malignant transformation occurs, both to improve
survival and to achieve a worthwhile, less toxic palliation.
In this case, as well as in others previously described,
EGFR signaling was activated in RRP, and is likely to have
driven the growth of the papilloma. Wu et al. showed that,
in papilloma-derived epithelial cells, EGFR, Rac1, and
COX-2 act in a linear pathway with EGFR upstream of
Rac1, which in turn results in increased expression of
COX-2 (Wu et al. 2007). Inhibition of this pathway using
the selective COX-2 inhibitor celecoxib reduced papilloma
cell proliferation and increased the rate of apoptosis.
Furthermore, a proof-of principle study of three patients
with severe RRP treated with celecoxib showed disease
remission in all cases (Lucs et al. 2012).
Conclusion
Although further investigation is necessary before the
clinical application of molecular targeted therapies, ourresults can serve as a foundation for the development of
novel therapeutic strategies including molecular targeted
therapy of EGFR signaling for severe RRP.
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